Predictive biomarkers for bevacizumab in the first line treatment of ovarian cancer

被引：0
|
作者：
Jayson, Gordon [1 ,2 ]
机构：
[1] Christie Hosp, Manchester, Lancs, England
[2] Univ Manchester, Manchester M13 9PL, Lancs, England
来源：
ANGIOGENESIS | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
O-39
引用
收藏
页码：727 / 727
页数：1
相关论文
共 50 条
  • [31] Bevacizumab Combination Therapy For the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    Dhillon, Sohita
    [J]. DRUGS, 2012, 72 (07) : 917 - 930
  • [32] Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer
    Barnett, I.
    Alvarez-Secord, A.
    Cohn, D.
    Leath, C.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S66 - S66
  • [33] Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
    Ferrara, Napoleone
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)
  • [34] Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer
    Kuronya, Zsofia
    Szonyi, Mihaly Daniel
    Nagyivanyi, Krisztian
    Gyergyay, Fruzsina
    Geczi, Lajos
    Budai, Barna
    Martin, Tamas
    Ladanyi, Andrea
    Kiss, Edina
    Biro, Krisztina
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2475 - 2481
  • [35] First-line treatment of ovarian cancer: Proof and promise
    Runowicz, CD
    [J]. GYNECOLOGIC ONCOLOGY ISSUES IN THE 8TH IGCS MEETING OF BUENOS AIRES, 2000, : 3 - 6
  • [36] Procedures after first-line treatment of ovarian cancer
    Thomssen, C
    [J]. ONKOLOGIE, 1999, 22 : 27 - 28
  • [37] Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
    Monberg, Matthew J.
    Hall, Jennifer P.
    Moon, Rebecca
    Higson, Olivia
    McLaurin, Kimmie
    Dalvi, Tapashi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer
    Mehta, Darshan A.
    Hay, Joel W.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 677 - 683
  • [39] Downstream effects of first line bevacizumab (bev) on outcomes after recurrence in advanced ovarian cancer
    Bishop, E.
    Perry, L.
    Previs, R.
    Alvarez-Secord, A.
    Moore, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S110 - S110
  • [40] Adding Bevacizumab to Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer
    Fox, Kevin R.
    [J]. CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 5 - 6
12345